Identification of the molecular basis of doxorubicin-induced cardiotoxicity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23104132.
- Also identified by DOI 10.1038/nm.2919.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen species (ROS). Here we show that cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-IIβ) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation. Furthermore, cardiomyocyte-specific deletion of Top2b protects mice from the development of doxorubicin-induced progressive heart failure, suggesting that doxorubicin-induced cardiotoxicity is mediated by topoisomerase-IIβ in cardiomyocytes.
Medical subject headings
- Cardiotoxins
- Doxorubicin
- Mitochondrial Turnover
- Myocytes, Cardiac